162 related articles for article (PubMed ID: 11751113)
21. Fluoroquinolone resistance in Streptococcus pneumoniae in United States since 1994-1995.
Brueggemann AB; Coffman SL; Rhomberg P; Huynh H; Almer L; Nilius A; Flamm R; Doern GV
Antimicrob Agents Chemother; 2002 Mar; 46(3):680-8. PubMed ID: 11850248
[TBL] [Abstract][Full Text] [Related]
22. Comparative in vitro activity and pharmacodynamics of five fluoroquinolones against clinical isolates of Streptococcus pneumoniae.
Kays MB; Conklin M
Pharmacotherapy; 2000 Nov; 20(11):1310-7. PubMed ID: 11079279
[TBL] [Abstract][Full Text] [Related]
23. AUC(0-t)/MIC is a continuous index of fluoroquinolone exposure and predictive of antibacterial response for Streptococcus pneumoniae in an in vitro infection model.
Zelenitsky SA; Ariano RE; Iacovides H; Sun S; Harding GK
J Antimicrob Chemother; 2003 Apr; 51(4):905-11. PubMed ID: 12654762
[TBL] [Abstract][Full Text] [Related]
24. Comparative pharmacodynamics of the new fluoroquinolone ABT492 and levofloxacin with Streptococcus pneumoniae in an in vitro dynamic model.
Firsov AA; Alferova IV; Smirnova MV; Lubenko IY; Portnoy YA; Zinner SH
Int J Antimicrob Agents; 2005 May; 25(5):409-13. PubMed ID: 15848296
[TBL] [Abstract][Full Text] [Related]
25. Comparison of gatifloxacin and levofloxacin administered at various dosing regimens to hospitalised patients with community-acquired pneumonia: pharmacodynamic target attainment study using North American surveillance data for Streptococcus pneumoniae.
Noreddin AM; Hoban DJ; Zhanel GG
Int J Antimicrob Agents; 2005 Aug; 26(2):120-5. PubMed ID: 16046101
[TBL] [Abstract][Full Text] [Related]
26. Pharmacodynamics of gemifloxacin against Streptococcus pneumoniae in an in vitro pharmacokinetic model of infection.
MacGowan AP; Rogers CA; Holt HA; Wootton M; Bowker KE
Antimicrob Agents Chemother; 2001 Oct; 45(10):2916-21. PubMed ID: 11557490
[TBL] [Abstract][Full Text] [Related]
27. Pharmacodynamics of the new des-f(6)-quinolone garenoxacin in a murine thigh infection model.
Andes D; Craig WA
Antimicrob Agents Chemother; 2003 Dec; 47(12):3935-41. PubMed ID: 14638504
[TBL] [Abstract][Full Text] [Related]
28. Pharmacodynamics of trovafloxacin, ofloxacin, and ciprofloxacin against Streptococcus pneumoniae in an in vitro pharmacokinetic model.
Lister PD; Sanders CC
Antimicrob Agents Chemother; 1999 May; 43(5):1118-23. PubMed ID: 10223923
[TBL] [Abstract][Full Text] [Related]
29. In vitro pharmacodynamic evaluation of the mutant selection window hypothesis using four fluoroquinolones against Staphylococcus aureus.
Firsov AA; Vostrov SN; Lubenko IY; Drlica K; Portnoy YA; Zinner SH
Antimicrob Agents Chemother; 2003 May; 47(5):1604-13. PubMed ID: 12709329
[TBL] [Abstract][Full Text] [Related]
30. Activities of moxifloxacin against, and emergence of resistance in, Streptococcus pneumoniae and Pseudomonas aeruginosa in an in vitro pharmacokinetic model.
MacGowan AP; Rogers CA; Holt HA; Bowker KE
Antimicrob Agents Chemother; 2003 Mar; 47(3):1088-95. PubMed ID: 12604546
[TBL] [Abstract][Full Text] [Related]
31. Comparative pharmacodynamics of moxifloxacin and levofloxacin in an in vitro dynamic model: prediction of the equivalent AUC/MIC breakpoints and equiefficient doses.
Firsov AA; Lubenko IY; Vostrov SN; Kononenko OV; Zinner SH; Portnoy YA
J Antimicrob Chemother; 2000 Nov; 46(5):725-32. PubMed ID: 11062191
[TBL] [Abstract][Full Text] [Related]
32. Antistaphylococcal effect related to the area under the curve/MIC ratio in an in vitro dynamic model: predicted breakpoints versus clinically achievable values for seven fluoroquinolones.
Firsov AA; Lubenko IY; Vostrov SN; Portnoy YA; Zinner SH
Antimicrob Agents Chemother; 2005 Jul; 49(7):2642-7. PubMed ID: 15980331
[TBL] [Abstract][Full Text] [Related]
33. Pharmacodynamics of moxifloxacin, levofloxacin and sparfloxacin against Streptococcus pneumoniae.
Lister PD; Sanders CC
J Antimicrob Chemother; 2001 Jun; 47(6):811-8. PubMed ID: 11389113
[TBL] [Abstract][Full Text] [Related]
34. Mechanism of fluoroquinolone resistance is an important factor in determining the antimicrobial effect of gemifloxacin against Streptococcus pneumoniae in an in vitro pharmacokinetic model.
MacGowan AP; Bowker KE
Antimicrob Agents Chemother; 2003 Mar; 47(3):1096-100. PubMed ID: 12604547
[TBL] [Abstract][Full Text] [Related]
35. Pharmacodynamics of trovafloxacin and levofloxacin against Bacteroides fragilis in an in vitro pharmacodynamic model.
Peterson ML; Hovde LB; Wright DH; Brown GH; Hoang AD; Rotschafer JC
Antimicrob Agents Chemother; 2002 Jan; 46(1):203-10. PubMed ID: 11751135
[TBL] [Abstract][Full Text] [Related]
36. Anti-pneumococcal activity of gatifloxacin compared with other quinolone and non-quinolone agents.
Hoellman DB; Lin G; Jacobs MR; Appelbaum PC
J Antimicrob Chemother; 1999 May; 43(5):645-9. PubMed ID: 10382885
[TBL] [Abstract][Full Text] [Related]
37. Pharmacodynamics of levofloxacin and ciprofloxacin in a murine pneumonia model: peak concentration/MIC versus area under the curve/MIC ratios.
Scaglione F; Mouton JW; Mattina R; Fraschini F
Antimicrob Agents Chemother; 2003 Sep; 47(9):2749-55. PubMed ID: 12936969
[TBL] [Abstract][Full Text] [Related]
38. Activities of mutant prevention concentration-targeted moxifloxacin and levofloxacin against Streptococcus pneumoniae in an in vitro pharmacodynamic model.
Allen GP; Kaatz GW; Rybak MJ
Antimicrob Agents Chemother; 2003 Aug; 47(8):2606-14. PubMed ID: 12878526
[TBL] [Abstract][Full Text] [Related]
39. Twenty-four-hour area under the concentration-time curve/MIC ratio as a generic predictor of fluoroquinolone antimicrobial effect by using three strains of Pseudomonas aeruginosa and an in vitro pharmacodynamic model.
Madaras-Kelly KJ; Ostergaard BE; Hovde LB; Rotschafer JC
Antimicrob Agents Chemother; 1996 Mar; 40(3):627-32. PubMed ID: 8851583
[TBL] [Abstract][Full Text] [Related]
40. Concentration-dependent changes in the susceptibility and killing of Staphylococcus aureus in an in vitro dynamic model that simulates normal and impaired gatifloxacin elimination.
Firsov AA; Vostrov SN; Lubenko IY; Zinner SH; Portnoy YA
Int J Antimicrob Agents; 2004 Jan; 23(1):60-6. PubMed ID: 14732315
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]